SEC Form 4	
------------	--

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5

obligations may continue. See

Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 193	21
Filed pursuant to Section 10(a) of the Securities Exchange Act of 193	4
or Section 30(h) of the Investment Company Act of 1940	

	1. Name and Addre <u>Carey John F</u>	1 6	J Person [*]	2. Issuer Name and Ticker or Trading Symbol <u>TransMedics Group, Inc.</u> [TMDX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner
(Last) (First) (Middle) C/O TRANSMEDICS GROUP, INC. 200 MINUTEMAN ROAD				3. Date of Earliest Transaction (Month/Day/Year) 04/05/2021	X Officer (give title Other (specify below) VP of Operations
(Street) ANDOVER M		MA (State)	01810 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	cution Date, Transaction					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V		Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)
Common Stock	04/05/2021		M ⁽¹⁾		3,360	A	\$16.14	3,360	D	
Common Stock	04/05/2021		S ⁽¹⁾		760	D	\$34.43(2)	2,600	D	
Common Stock	04/05/2021		S ⁽¹⁾		800	D	\$35.99 ⁽³⁾	1,800	D	
Common Stock	04/05/2021		S ⁽¹⁾		1,000	D	\$37.62(4)	800	D	
Common Stock	04/05/2021		S ⁽¹⁾		600	D	\$38.68(5)	200	D	
Common Stock	04/05/2021		S ⁽¹⁾		200	D	\$40.48(6)	0	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

	(e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$16.14	04/05/2021		M ⁽¹⁾			3,360	(7)	02/27/2030	Common Stock	3,360	\$0.00	11,640	D	

Explanation of Responses:

1. The reported transactions were effected pursuant to a Rule 10b5-1 trading plan.

The price reported is a weighted average price. These shares were sold in multiple transactions ranging from \$34.17 to \$34.78, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from \$37.01 to \$36.48, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from \$37.01 to \$38.00, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from \$38.09 to \$39.08, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from \$38.09 to \$39.08, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.</

Remarks:

/s/ Stephen Gordon, Attorney-04/06/2021

<u>in-Fact</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.